Beta bloccanti

<p>Impurity Atenolol Impurity 3; Atenolol Impurity 1<br>Applications Atenolol Impurity 3. Atenolol Impurity 1.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>

<p>Impurity Timolol EP Impurity A; Timolol BP Impurity A; Timolol USP Related Compound A<br>Applications (R)-Timolol (Timolol EP Impurity A; Timolol BP Impurity A; Timolol USP Related Compound A) is an antihypertensive agent that increases ocular blood flow and reduces intraocular pressure. (R)-Timolol is an β-adrenergic blocking agent that binds only to nonspecific sites in the particulate fraction of the heart, lungs, and brain.<br>References Rotmensch, H. et al.: J. Clinical. Pharmacol., 33, 544 (1993); Chiou, G. &amp; Chen. Y., J. Ocular. Pharmacol., 8, 183 (1992); Chiou, G. et al.: J. Ocular. Pharmacol., 6, 23 (1990); Tocco, D. et al.: Drug Met. Disposit., 4, 323 (1976)<br></p>

<p>Applications Labelled Dopamine. Endogenous catecholamine with α and β-adrenergic activity. Cardiotonic; antihypotensive.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Carter, J.E., et al.: Anal. Profiles Drug Subs., 11, 257 (1982), Dasta, J.F., et al.: Pharmacotherapy, 6, 304 (1986),<br></p>

<p>Impurity Rosuvastatin EP Impurity F<br>Applications (4R,6S)-6-[(1E)-2-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-Dimethylethyl Ester (Rosuvastatin EP Impurity F) is a Rosuvastatin (R700500) intermediate as HMG-CoA reductase inhibitor.<br>References Beck, et al.: J. Med. Chem., 33, 52 (1999),<br></p>

<p>Applications Bopindolol is an ester prodrug of Pindolol (P468000). Bopindolol is a long acting β-adrenoceptor blocking agent. Bopindolol displays antispasmogenic activity mediated by α1-adrenoceptors and 5-HT2 receptors.<br>References Turner, D.R. et al.: Br. J. Clin. Pharmacol., 17, 295 (1984); Brodde, O.E. et al.: J. Cardio. Pharmacol., 8, S70 91986); Doggrell, S.A.: Med, Sci. Res., 17, 681 (1989);<br></p>

<p>Applications Cardioselective β-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic (class II).<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984),<br></p>

<p>Impurity Rosuvastatin EP Impurity G<br>Stability Hygroscopic<br>Applications ent-Rosuvastatin is an enantiomer of Rosuvastatin (R700500), an impurity which acts as a selective, competitive HMG-CoA reductase inhibitor (1). Antilipemic (2,3).<br>References 1. Watanabe, M. et al.: Bioorg. Med. Chem. 1997 Feb;5(2):437-44.2. Lee, E. et al.: Clin. Pharmacol. Ther. 2005 Oct;78(4):330-41.3. Ferdinand, C. et al.: Am. J. Cardiol. 2006 Jan 15;97(2):229-35.<br></p>

<p>Impurity Metoprolol EP Impurity O<br>Applications 1,1’-[(1-Methylethyl)imino]bis[3-[4-(2-methoxyethyl)phenoxy]-2-propanol (Metoprolol EP Impurity O) is an impurity of Metoprolol.<br>References Gyllenhaal, O., et al.: J. Biochem. Biophys. Methods, 43, 135 (2000), Chester, T., et al.: Anal. Chem., 74, 2801 (2002),<br></p>

<p>Impurity Atenolol Desmethyl Impurity<br>Applications Cis-Desmethyl Atenolol is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker and antihypertensive agent. Atenolol Desmethyl Impurity<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984);<br></p>

<p>Applications Labelled Nadolol (N201052). β-Adrenergic blocker. Antihypertensive; antianginal.<br>References Dreyfuss, J., et al.: J. Clin. Pharmacol., 17, 300 (1977), Sibley, P.L., et al.: Toxicol. Appl. Pharmacol., 44, 379 (1978), Slusarek, L., et al.: Anal. Profiles Drug Subs., 9, 455 (1980),<br></p>

<p>Impurity Olmesartan Medoxomil EP Impurity D<br>Applications Olmesartan medoxomil intermediate.<br>References Birkenhager, W., et al.: J. Hypertens, 17, 873 (1999), Whittaker, A., et al.: Br. J. Cardiol., 12, 125 (2005),<br></p>

<p>Impurity Atenolol EP Impurity D<br>Applications 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker. Atenolol EP Impurity D<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984); Pai, N.R., et al.: J. Chem. Pharma. Rsch., 4, 375 (2012);<br></p>